Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Solx Inc.

Reinvigorating a natural pathway to relieve intraocular pressure

This article was originally published in Start Up

Executive Summary

The gold standard for treating refractory glaucoma, trabeculectomy creates an artificial pathway to relieve intraocular pressure by forming an external bleb or blister under the eyelid so that aqueous humor fluid can drain from inside the eye to the bleb. Solx Inc. has developed an implantable device that improves on that method. The Solx Gold Shunt is a flat tube that detours fluid within the eye by using an existing pathway (the suprachoroidal space) that gradually shuts down as one ages. The shunt reconnects and reinvigorates this outflow pathway.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel